Thanks. We apparently see things differently. I believe Raj has become a liability in spite of his original efforts. It appears he worked hard to create a cash cow that his is now milking.
1. Ancient History. 2. Ancient History. 3. At what cost to Shareholders? 4. Agreed - That, and hating to loose money, is why I am still here. That said, Raj's presence will serve to diminish the potential of any share price momentum resulting from any drug approvals, both in peak price and price sustainability. 5. I don�t think there was any real cost benefit analysis with respect to generics. Costs appear to be outweighing revenue. I am now underwhelmed. Generics are rapidly appearing to be marketing window dressing. 6. Agreed, but not particularly positive. 7. Until Raj stops being the "front man" this makes little to no difference. 8. Only if there are positive words to get out and competent PR people to do it (e.g. not Raj).